Menu

Top Stories

Vertex, CRISPR’s gene-editing treatment for blood disorders shows promise in early data

Vertex, CRISPR’s gene-editing treatment for blood disorders shows promise in early data
Wednesday, November 20, 2019
CRISPR Therapeutics and Vertex Pharmaceuticals unveiled early data from the first company-backed study to test a CRISPR-based medicine in humans. The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment for patients who need chronic care, wrote Cantor Fitzgerald analysts in a note.  The treatment, CTX001, is in two...
Divider

Foundation presents Building Friends for a Cure awards

Monday, June 14, 2010
ORLANDO, FL—The Alpha-1 Foundation presented its Building Friends for a Cure awards Friday evening during the Alpha-1 Association’s annual educational conference. The Alpha-1 Foundation presented awards to the following. All-Star...
Divider

Alpha-1 protein to be tested as treatment for Type 1 diabetes

Wednesday, June 9, 2010
MarketWire DENVER, CO—Omni Bio Pharmaceutical, Inc. announced that the Barbara Davis Center for Childhood Diabetes has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I and II clinical...
Divider

Childhood liver disease studies enrolling patients; some travel funds available to eligible families

Tuesday, June 8, 2010
The Childhood Liver Disease Research and Education Network (ChiLDREN) is enrolling children now for vital research studies on cholestatic liver diseases of children. In cholestatic liver disease, the flow of bile from the liver into the digestive...
Divider

Grifols, Talecris press release on planned acquisition

Monday, June 7, 2010
PR Newswire BARCELONA, Spain and RESEARCH TRIANGLE PARK, NC—Grifols a global healthcare company and leading producer of plasma protein therapies, and Talecris, a US-based biotherapeutics products company, today announced that they have...
Divider

Spanish company Grifols to acquire Talecris for $3.4 billion

Monday, June 7, 2010
Reuters Spain’s Grifols has agreed to buy US-based Talecris Biotherapeutics, which makes plasma-based protein therapies, for $3.4 billion in a bold move to expand its business in blood products. Talecris is the manufacturer of Prolastin,...
Divider

Marta Strock dies; one of first AlphaNet coordinators

Monday, June 7, 2010
Marta Strock was one of the first AlphaNet coordinators, and proud of it. “As an AlphaNet coordinator,” she told a magazine writer in 2004, “I have the opportunity to bring a wealth of knowledge about our disease to many Alphas...
Divider

Anti-seizure drug improves liver disease in Alpha-1 mice

Friday, June 4, 2010
A note from Robert A. Sandhaus, MD, PhD, clinical director of the Alpha-1 Foundation and medical director of AlphaNet: In the interest of presenting the latest information to our Alpha-1 community, the following press release has been posted...
Divider

Whom to test, whom to treat, for Alpha-1?

Friday, June 4, 2010
An examination of the current issues in testing and treating for Alpha-1 has been published by Robert A. Sandhaus, MD, PhD, in the journal Seminars in Respiratory and Critical Care Medicine. Sandhaus is clinical director of the Alpha-1...
Divider
First61626364656667686970

Article Search

Enter keywords in text box and click Search button for results.

Archive